Form 4: Evolent Health Director Shawn Guertin Awarded 21,979 Restricted Stock Units

Evolent Health, Inc. (EVH) Director Shawn M. Guertin has been granted 21,979 restricted stock units (RSUs) as part of the company's incentive compensation plan.

Summary

• Shawn M. Guertin, a Director at Evolent Health, Inc. (EVH), was granted 21,979 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• The transaction occurred on June 5, 2025, with an acquisition price of $0 per unit, which is typical for equity grants.
• These RSUs were granted pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• Following this transaction, Mr. Guertin beneficially owns 21,979 shares directly.
• The securities are set to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent upon Mr. Guertin's continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders, a common and generally well-regarded practice in corporate governance. It is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a standard form of equity compensation, indicating ongoing commitment to executive and director incentives.

Future Outlook

The restricted stock units granted to Director Shawn M. Guertin are scheduled to vest on the earlier of June 5, 2026, or the date of Evolent Health's 2026 annual meeting, provided he continues his service to the company.

Industry Context

Equity grants, such as restricted stock units, are a common practice in the healthcare technology and services industry to attract, retain, and incentivize key directors and executives, aligning their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The grant represents a form of equity compensation that aligns the director's incentives with shareholder value creation, though it also involves potential future dilution upon vesting.
• Director (Shawn M. Guertin): Receives equity compensation, incentivizing long-term commitment and performance.

Next Steps

• The restricted stock units will vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, subject to the reporting person's continued service.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Insider Transaction, Restricted Stock Units, RSU, Shawn M. Guertin, Director, Equity Compensation, SEC Filing